Treatment Strategies in Hepatocellular Carcinoma (HCC): Optimizing Outcomes and Resource Allocation

A panel of medical experts open a discussion surrounding key treatment strategies in management of hepatocellular carcinoma (HCC).

Ghassan Abou-Alfa, MD, MBA, and Mohamed Salem, MD, provide insights regarding potential clinical pathway-driven challenges associated with HCC management.

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC.

Benefits of clinical pathway implementation in HCC management are examined.

Medical experts discuss patient considerations when utilizing clinical pathways in HCC treatment.

An overview of the HIMALAYA study and IMbrave150 trial are provided.

Expert panelists discuss key factors contributing to “time to response” in HCC treatment, and its impact on patient prognosis.

Dr Abou-Alfa discusses strategies to mitigate the impact of adverse events in patients receiving treatment for HCC.

Treatment continuity and adherence in HCC can be encouraged through patient education and engagement.

Cost-effectiveness considerations are highlighted by Dr Abou-Alfa.

The decision to perform an EGD is evaluated between academic and community health care perspectives.

Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.

Dr Haumschild leads a discussion surrounding toxicity profiles specifically related to HCC.

Toxicity management in HCC treatment is discussed by medical experts.

Dr Salem opens a conversation highlighting the impact of toxicity profiles on a patient’s quality of life, and Dr. Abou-Alfa examines the consequences of treatment-related toxicities in HCC on the utilization of healthcare resources.

Medical experts offer strategies for assessing and allocating health care resources in HCC management.

The panelists provide their closing thoughts from a discussion highlighting key considerations in treatment and management of HCC.